leisure time -WSS

leisure time

author：Wikipedia 2025-09-28 00:53:59 - browse：24

This is the inaugural edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Hello! Welcome to the premiere issue of Adam’s Biotech Scorecard. I’m excited to get started. Let’s do this! (By the way, the AF in the logo are my initials, not the “other” AF.)

The contrarian view of Viking Therapeutics

Closeup financial chart

The developer of a dual-acting GLP-1/GIP treatment for obesity is riding high on positive data and takeout speculation. The drug, called VK2735, has shown impressive weight loss with minimal gastrointestinal side effects in both subcutaneous and oral formulations, positioning it as a strong challenger to the obesity juggernauts from Eli Lilly and Novo Nordisk. With a stock price that has soared nearly 800% over the past year, Viking is now a $9 billion company and a prime acquisition target for a cash-rich pharma company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Late stage cancers on the rise after pandemic delayed screenings

hotspot

WSS

Study says nonprofit hospitals fall short in charity care spending

It costs an awful lot of money to give away a kidney

Medicare slashes safety net hospital payments by nearly $1 billion

Study links childhood stress with decline in older age

Roche subsidiary Foundation Medicine opens new headquarters

Abortion pill case raises question: who can sue the FDA?

knowledge

leisure time

The contrarian view of Viking Therapeutics

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Abortion pill case raises question: who can sue the FDA?

Dobbs anniversary: the lost opportunity of abortion as health care

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Medicare details structure of new drug price negotiation program

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

United colonoscopy coverage change 'may cost lives,' doctors say

Abortion pill case raises question: who can sue the FDA?

As demand for Covid shots wanes, Moderna seeks its next success

Physicians aren't 'burning out.' They're suffering from moral injury

leisure time

Roche subsidiary Foundation Medicine opens new headquarters

Flint parents haunted by uncertainty, fears of lead poisoning

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Physicians aren't 'burning out.' They're suffering from moral injury

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

The Readout: Lenmeldy, GLP

Wikipedia

hotspot

explore

focus